Search
forLearn
5 / 801 resultslearn HT-B
learn sh-Polypeptide-7
learn phosphorus
learn Isopropylmethylphenol
Research
5 / 1000+ results
research Quality of life case series review: wound bed preparation from a UK perspective
PHMB products improve wound healing and quality of life.
research In vivo investigation of the efficiency of a nanoparticle-emulsion containing polihexanide on the human skin
The nanoparticle-emulsion with polihexanide is more effective and lasts longer for skin antisepsis.
research Lithium therapy associated with hidradenitis suppurativa: Case report and a review of the dermatologic side effects of lithium
Lithium therapy may cause skin problems like hidradenitis suppurativa and other side effects, which can improve after stopping the medication.
research Regeneration of Chronic Wounds with Allogeneic Platelet Gel versus Hydrogel Treatment: a Prospective Study
Allogeneic platelet gel heals chronic wounds better than hydrogel.
research Review of the Latest Methods of Epidermolysis Bullosa and Other Chronic Wounds Treatment Including BIOOPA Dressing
New treatments for epidermolysis bullosa show promise in improving patients' lives, but a cure is still not available.
Community Join
5 / 1000+ resultscommunity MPB since 16. 31 now, recovering from PFS, and getting back in the game.
User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
community Oral PTD-DBM available online, worth giving a shot?
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.